AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT04300621
Drug: OTF 2
RxNorm normalized name: Oxycodone Hydrochloride and Naloxone Hydrochloride Extended-Release Tablets
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive (S)-ketamine administered sublingually through OTF 2.
Trial: NCT04300621
Drug: OTF 3
RxNorm normalized name: Oxycodone Hydrochloride and Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive (S)-ketamine administered sublingually through OTF 3.
Trial: NCT04300621
Drug: OTF 4
RxNorm normalized name: Oxycodone Hydrochloride and Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive (S)-ketamine administered sublingually through OTF 4.
Trial: NCT05014906
Drug: Azelaic acid
RxNorm normalized name: Azelaic Acid
DrugBank: Azelaic acid (DB00548)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 45 mg oral minocyclineonce daily vs 45mg oral minocycline once daily in combination with use of 15% azelaic acid
Trial: NCT00306878
Drug: Abatacept
RxNorm normalized name: Abatacept
DrugBank: Abatacept (DB01281)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02391545
Drug: Duvelisib
RxNorm normalized name: Duvelisib
DrugBank: Duvelisib (DB11952)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: PI3K Inhibitor
Trial: NCT02391545
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: monoclonal antibody
Trial: NCT02391545
Drug: Obinutuzumab
RxNorm normalized name: Obinutuzumab
DrugBank: Obinutuzumab (DB08935)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: monoclonal antibody
Trial: NCT02990364
Drug: Sucrose
RxNorm normalized name: Sucrose
DrugBank: Sucrose (DB02772)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sucrose was given to three out of the 4 intervention groups, to assess its effectiveness in managing pain during circumcision.
Trial: NCT02990364
Drug: Lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lidocaine was given as a local anesthetic via Ring and Dorsal Penile Block to two of the intervention groups, in combination with the topical cream EMLA and sucking on sucrose.
Trial: NCT04149587
Drug: Brodalumab
RxNorm normalized name: Brodalumab
DrugBank: Brodalumab (DB11776)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Brodalumab will be administered per dose and schedule specified in the arm.
Trial: NCT00261625
Drug: alendronate
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02968121
Drug: Brexpiprazole, OPDC-34712
DrugBank: Brexpiprazole (DB09128)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04670289
Drug: TenoMiR (Low Dose)
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mimic of miR29a
Trial: NCT04670289
Drug: TenoMiR (High Dose)
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mimic of miR29a
Trial: NCT03438461
Drug: Seltorexant 40 mg
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant 40 mg as two tablets of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 1.
Trial: NCT03438461
Drug: Seltorexant 20 mg
RxNorm normalized name: Seltorexant
DrugBank: Seltorexant (DB14961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Seltorexant as a tablet of 20 mg will be administered as Formulation 1, 2 and 3 orally in Part 2.
Trial: NCT04062448
Drug: Ibrutinib
RxNorm normalized name: Ibrutinib
DrugBank: Ibrutinib (DB09053)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ibrutinib 420 mg will be administered orally.
Trial: NCT04062448
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m\^2 will be administered intravenously.
Trial: NCT02541955
Drug: Acthar
RxNorm normalized name: Acthar
DrugBank: Corticotropin (DB01285)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Injections will be self administered
Trial: NCT03441750
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin tablets will be administrated in the experimental arm.
Trial: NCT00705042
Drug: Etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02189122
Drug: Bradykinin
RxNorm normalized name: Bradykinin
DrugBank: Bradykinin (DB12126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bradykinin will be given intravenously in graded doses. Each dose will be given for 15 minutes.
Trial: NCT02189122
Drug: Aspirin 81 mg
RxNorm normalized name: aspirin 81 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take Aspirin 81 mg per day for five days.
Trial: NCT02189122
Drug: Aspirin 162 mg
RxNorm normalized name: aspirin 162 MG
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take aspirin 162 mg per day for 5 days.
Trial: NCT02189122
Drug: NHP544-C 81 mg
RxNorm normalized name: Vitamin C
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will take NHP544C 81 mg per day for five days.
Trial: NCT04026074
Drug: Clonidine
RxNorm normalized name: Clonidine
DrugBank: Clonidine (DB00575)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Weight adapted drug application
Trial: NCT04026074
Drug: EMLA Cream
RxNorm normalized name: LIDOCAINE 25 mg in 1 g / PRILOCAINE 25 mg in 1 g TOPICAL CREAM [Emla Cream]
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salve application on the body part where the regional anaesthesia will be administered
Trial: NCT02264353
Drug: Donepezil
RxNorm normalized name: Donepezil
DrugBank: Donepezil (DB00843)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Donepezil 10mg before sleep
Trial: NCT00581009
Drug: sertraline, lithium
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Antidepressant, Subjects will be started on a serotonin specific reuptake inhibitor (SSRI), sertraline 100 mg (50mg hs x 2) daily or other SSRI's such as Paxil 20 mg or Prozac 20 mg daily and continue treatment for seven weeks.~Mood stabilizer, subjects will be treated with lithium 450 mg twice a day or another mood stabilizer such as depakote or valproate and continue treatment for seven weeks.
Trial: NCT03194815
Drug: Intravenous immunoglobulin
RxNorm normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a blood product containing antibodies from thousands of healthy donors.
Trial: NCT03194815
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab is a type of biological therapy. It removes B-cells and helps to reduce the inflammation
Trial: NCT02864147
Drug: 9-valent HPV vaccine
RxNorm normalized name: L1 protein, human papillomavirus type 31 vaccine
DrugBank: Human papillomavirus type 31 L1 capsid protein antigen (DB10310)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All women (regardless of age) will be administered a dose of the HPV vaccine on day of enrollment (regardless of previous HPV vaccination history). Women previously unvaccinated will receive an additional booster dose at 8 weeks.
Trial: NCT02864147
Drug: Imiquimod
RxNorm normalized name: Imiquimod
DrugBank: Imiquimod (DB00724)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: At the baseline visit, this group will be instructed about the correct method of self-application of imiquimod 6.25mg as a vaginal suppository and receive a 16 week course of the drug.
Trial: NCT02968108
Drug: Ustekinumab
RxNorm normalized name: Ustekinumab
DrugBank: Ustekinumab (DB05679)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Subjects will receive a single IV administration of ustekinumab (3 mg/kg for subjects \<40 kg or 130 mg for subjects \>= 40 kg in Group 1 and 9 mg/kg for subjects \< 40 kg or 390 mg for subjects \>= 40 kg in group 2) at week 0 followed by SC administration of ustekinumab (2 mg/kg for subjects \< 40 kg or 90 mg for subjects \>= 40 kg at Week 8.
Trial: NCT03600090
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxol will be IV injection
Trial: NCT00806741
Drug: NG-monomethyl-L-arginine (L-NMMA)
RxNorm normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: bolus 6mg/kg over 5 minutes followed by a continuous infusion of 60µg/kg/min over 15 minutes
Trial: NCT00806741
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1μg/kg/min, infusion period 20 minutes
Trial: NCT01086878
Drug: cotrimoxazole
RxNorm normalized name: Clotrimazole
DrugBank: Clotrimazole (DB00257)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily oral cotrimoxazole suspension from 1 to 6 months of age at the following weight-based doses:~* less than 5kg: 100mg sulfamethoxazole, 20mg trimethoprim~* greater than 5kg: 200mg sulfamethoxazole, 40mg trimethoprim
Trial: NCT01042145
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2 mgs/kg for 3 days
Trial: NCT01042145
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.6 mgs for one day, then placebo for 2 days
Trial: NCT02382016
Drug: Macitentan
RxNorm normalized name: Macitentan
DrugBank: Macitentan (DB08932)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Macitentan film-coated tablet 10 mg once daily.
Trial: NCT03976843
Drug: 18F-DCFPyL
RxNorm normalized name: 18F-DCFPyL
DrugBank: Piflufolastat F 18 (DB14805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18F-labeled agent that is a high affinity small molecule inhibitor of PSMA to detect prostate cancer via PET imaging
Trial: NCT00768209
Drug: Phentermine and Topiramate
RxNorm normalized name: phentermine and topiramate
DrugBank: Phentermine (DB00191)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Each subject will be dosed with a single oral dose of VI-0521 (PHEN/TPM 15/92 mg).
Trial: NCT01965041
Drug: aflibercept
RxNorm normalized name: Aflibercept
DrugBank: Aflibercept (DB08885)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 2.0 mg intravitreal aflibercept injection is formulated as a sterile liquid to a final concentration of 40 mg/mL aflibercept in 5% sucrose, 10 mM sodium phosphate pH 6.3, 0.03% polysorbate 20, and 40 mM NaClvs. placebo
Trial: NCT00926302
Drug: Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 500mg/tablet Oral once
Trial: NCT00926302
Drug: Keppra (Levetiracetam - USB SA Pharma Sector)
RxNorm normalized name: levetiracetam Injection [Keppra]
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levetiracetam 500mg/tablet oral once
Trial: NCT04340141
Drug: Oxaliplatin
RxNorm normalized name: Oxaliplatin
DrugBank: Oxaliplatin (DB00526)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT04340141
Drug: Irinotecan Hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00006436
Drug: EPOCH
RxNorm normalized name: Epoch Blemish
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: combination chemotheray: EPOCH every 3 weeks for minimum of 3 cycles and max of 6 cycles
Trial: NCT03547024
Drug: JNJ-55308942 High Dose
RxNorm normalized name: high-density polyethylene
DrugBank: JNJ-55308942 (DB19110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive high dose of JNJ-55308942 orally once daily.
Trial: NCT03547024
Drug: JNJ-55308942 Low Dose
RxNorm normalized name: ethinyl estradiol
DrugBank: JNJ-55308942 (DB19110)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive low dose of JNJ-55308942 orally once daily.
Trial: NCT03547024
Drug: Drug Cocktail:Midazolam (2mg)/Omeprazole (20mg)/Dextromethorphan (30mg)
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive single dose of drug cocktail consisting of midazolam (2 mg), dextromethorphan (30mg) and omeprazole (20 mg) orally.
Trial: NCT03379909
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin orally at doses up to 1500 mg twice daily for 3 months.
Trial: NCT00443599
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Study drug is continuously infused intravenous insulin. Suggested dose is calculated by a computerized infusion algorithm using the participant's blood sugar concentration. The insulin infusion rate is titrated to maintain normal blood sugar. Participants are eligible to receive insulin while they have an in-dwelling arterial catheter.
Trial: NCT01396733
Drug: alpha-lipoic acids
DrugBank: Lipoic acid (DB00166)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: alpha-lipoic acid 600 mg/day or 1,200 mg/day 600 mg/day - Three tablets (200mg x 3), one time per day for 3 months 1,200 mg/day - Three tablets (200mg x 3), two times per day for 3 months
Trial: NCT02767596
Drug: Lixisenatide
RxNorm normalized name: Lixisenatide
DrugBank: Lixisenatide (DB09265)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02767596
Drug: Basal insulins
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: patients are on basal insulin treatment
Trial: NCT02674555
Drug: radio-labeled naquotinib
RxNorm normalized name: strontium chloride, 89Sr-labeled
DrugBank: Naquotinib (DB12036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT02674555
Drug: naquotinib
RxNorm normalized name: Naquotinib
DrugBank: Naquotinib (DB12036)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration
Trial: NCT01266499
Drug: Colistin (Polymyxin E) 100mg x 4/d
DrugBank: Colistin (DB00803)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colistin (Polymyxin E) 100mg x 4/d
Trial: NCT02617667
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical ocular, eye drops
Trial: NCT01370512
Drug: Droxidopa
RxNorm normalized name: Droxidopa
DrugBank: Droxidopa (DB06262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100 mg tablets by mouth three times a day
Trial: NCT01370512
Drug: Pyridostigmine
RxNorm normalized name: Pyridostigmine
DrugBank: Pyridostigmine (DB00545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg tablets by mouth three times a day
Trial: NCT00427245
Drug: goserelin acetate
RxNorm normalized name: Goserelin Acetate
DrugBank: Goserelin (DB00014)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01502371
Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 25 mcg
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF MDI 25 mcg (per inhalation), 2 puffs BID for 12 weeks
Trial: NCT01502371
Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 50 mcg
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF MDI 50 mcg (per inhalation), 2 puffs BID for 12 weeks
Trial: NCT01502371
Drug: Mometasone Furoate (MF) Metered Dose Inhaler (MDI), 100 mcg
DrugBank: Mometasone (DB00764)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MF MDI 100 mcg (per inhalation), 2 puffs BID for 12 weeks
Trial: NCT01640080
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type= exact number, number= 0.20, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.20 mg/kg administered on Day 1 and Day 4.
Trial: NCT01640080
Drug: Esketamine
RxNorm normalized name: ESKETAMINE
DrugBank: Esketamine (DB11823)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Type= exact number, number= 0.40, unit= mg/kg, form= intravenous infusion, route= intravenous use. One single intravenous infusion of esketamine 0.40 mg/kg administered on Day 1 and Day 4.
Trial: NCT02139982
Drug: ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Different concentration of ropivacaine
Trial: NCT02971891
Drug: CLS006 (Furosemide) Topical Gel
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02971891
Drug: Vehicle Topical Gel
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04592536
Drug: CVL-865 High dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose CVL-865: Will be administered as 5mg BID for 2 days followed by 12.5mg BID for another 2 days during the Titration Phase. 25mg will be administered during the Maintenance Phase (3 days of BID and morning dose only on the 4th day)
Trial: NCT04592536
Drug: Alprazolam 1mg XR
DrugBank: Alprazolam (DB00404)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alprazolam 1mg XR will be administered for 8 days BID (morning dose only on 8th day)
Trial: NCT04592536
Drug: CVL-865 low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low dose CVL-865, oral tablets. Will be administered as 2.5mg BID for 2 days followed by 5mg BID for another 2 days during the Titration Phase. 7.5mg BID will be administered during the Maintenance Phase (3 days of BID and morning dose only on 4th day)
Trial: NCT02774343
Drug: Pioglitazone
RxNorm normalized name: Pioglitazone
DrugBank: Pioglitazone (DB01132)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
Trial: NCT03477461
Drug: terlipressin
RxNorm normalized name: Terlipressin
DrugBank: Terlipressin (DB02638)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: a continuous infusion of terlipressin (0.4 mg/kg/h) was initiated
Trial: NCT01705470
Drug: furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01705470
Drug: placebo normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03074045
Drug: Levonorgestrel (Kyleena, BAY86-5028)
RxNorm normalized name: Levonorgestrel
DrugBank: Levonorgestrel (DB00367)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years
Trial: NCT02985255
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Arm
Trial: NCT02985255
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Neoadjuvant Arm
Trial: NCT01554371
Drug: Eribulin
RxNorm normalized name: Eribulin
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Given intravenously (IV)~Phase II: Eribulin mesylate (mg/m2) + Cyclophosphamide (mg/ m2) for advanced breast cancer participants only
Trial: NCT00002855
Drug: Bicalutamide
RxNorm normalized name: Bicalutamide
DrugBank: Bicalutamide (DB01128)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002855
Drug: Estramustine Phosphate Sodium
RxNorm normalized name: Estramustine Phosphate Sodium
DrugBank: Estramustine (DB01196)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002855
Drug: Flutamide
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002855
Drug: Ketoconazole
RxNorm normalized name: Ketoconazole
DrugBank: Ketoconazole (DB01026)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002855
Drug: Nilutamide
RxNorm normalized name: Nilutamide
DrugBank: Nilutamide (DB00665)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00623415
Drug: Flupirtine
RxNorm normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg daily (divided in two doses)
Trial: NCT02936154
Drug: PF-06650833
RxNorm normalized name: PF-06650833
DrugBank: PF-06650833 (DB15143)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04368533
Drug: Livionex Dental Gel
RxNorm normalized name: VioNex
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The subjects will brush their teeth with Livionex Dental Gel twice a day for up to 12 months.
Trial: NCT03747159
Drug: Belimumab Injection
RxNorm normalized name: belimumab Injection
DrugBank: Belimumab (DB08879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Weekly injection of belimumab prior to two infusions of rituximab with continuation of the belimumab as maintenance therapy
Trial: NCT03049306
Drug: Propranolol Oral Tablet
RxNorm normalized name: propranolol Oral Tablet
DrugBank: Propranolol (DB00571)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients will receive Propranolol LA 80 mg PO at 7 PM before sleep (on CPAP withdrawal nights only)